Austrian start-up Hookipa raises €7 million in series A round

Austrian start-up company, Hookipa Biotech, has raised €7 million in a series A financing round led by Sofinnova Partners. Forbion Capital Partners also joined the syndicate as a co-investor.

Founded in July 2011, Hookipa specialises in developing new generation vaccines and said it would use the series A funds to advance its lead product HB101 through preclinical development and a Phase I proof of concept study, and to further industrialise and validate its proprietary Vaxwave technology. It is also in the process of establishing a supervisory board